UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934

 

May 3, 2006
Date of Report (Date of earliest event reported)

 

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

0-20045

 

95-3872914

(State or other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification Number)

 

 

 

 

 

311 Bonnie Circle

 

92880

Corona, California

 

(Zip Code)

(Address of principal executive
offices)

 

 

 

(951) 493-5300

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01                           Other Events.

 

On May 3, 2006, Watson Pharmaceuticals, Inc. (“Watson”) and Andrx Corporation (“Andrx”) issued a joint press release announcing that they have each received from the Federal Trade Commission a request for additional information (commonly referred to as a “second request”) pursuant to the notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Watson’s pending acquisition of Andrx.

 

For additional information concerning the foregoing, a copy of the joint press release dated May 3, 2006 is attached hereto as Exhibit 99.1.

 

Item 9.01   Financial Statements and Exhibits.

 

d.

Exhibit

 

 

 

99.1

News Release titled “Watson Pharmaceuticals and Andrx Corporation Receive FTC Second Request” dated May 3, 2006.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated:  May 3, 2006.

WATSON PHARMACEUTICALS, INC.

 

 

 

By:

  /s/David A. Buchen

 

 

 

David A. Buchen

 

 

Senior Vice President, General Counsel

 

 

and Secretary

 

3